Blueprint Medicines Stock Price - BPMC

65.445
0.305 (0.47%)
Upgrade to Real-Time
Regular Market
65.445
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.305 0.47% 65.445 64.69 65.92 65.32 65.14 10:10:29
Bid Price Ask Price Spread Spread % News
65.30 65.64 0.34 0.52% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
466 21,893 $ 65.27 $ 1,429,048 727,958 43.29 - 102.98
Last Trade Time Type Quantity Stock Price Currency
10:10:24 10 $ 65.59 USD

Blueprint Medicines Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.55B 54.19M 53.37M $ 66.51M $ - -7.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BPMC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week67.1168.3961.5065.40633,361-1.67-2.48%
1 Month56.9868.3956.0063.14598,7048.4714.86%
3 Months51.8872.3643.2959.66774,42013.5726.15%
6 Months81.4587.4343.2964.58748,713-16.01-19.65%
1 Year74.12102.9843.2971.04599,360-8.68-11.7%
3 Years35.76109.0034.66570.40482,45829.6983.01%
5 Years28.685109.0013.0460.35383,87536.76128.15%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.


Your Recent History
NASDAQ
BPMC
Blueprint ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.